SMAD3

Across TCGA pan-cancer cohorts, SMAD3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SMAD3 data layer compared with 21 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SMAD3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SMAD3 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

HNSC, PDAC, and CCRCC are the cancer types where SMAD3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	III,IV	0.319	0.871	.008	32	view →
PDAC	OS	Tertile	II,III,IV	0.636	0.318	.005	21	view →
CCRCC	OS	Median	II,III,IV	0.454	1.000	.014	8	view →
LUAD	OS	Tertile	II,III,IV	0.338	0.824	.017	4	view →
LSCC	OS	Quartile	II,III,IV	0.753	0.997	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SMAD3–HNSC (DFS)

Open the HNSC breakdown →